The aim is to confirm utility of 18 plasma biomarkers for detection of mild-to-moderate form of disease.

Satoris will initiate a collaborative study with the Mayo Foundation for Medical Education and Research to validate the utility of plasma biomarkers for early detection of mild-to-moderate Alzheimer’s disease. These biomarkers may also predict the progression of patients from a state of mild cognitive impairment to Alzheimer’s.

“We welcome the opportunity to collaborate with Mayo Clinic researchers in confirming the performance and utility of our blood test for Alzheimer’s,” says Cris McReynolds, president and CEO of Satoris. “Continued validation, we believe, will lead to commercial release of this test, initially for research use in late summer 2008 and ultimately for clinical use.”

Satoris researchers first reported the utility of Alzheimer’s–related biomarkers in the November, 2007 edition of Nature Medicine. In the reported study, the firm analyzed 259 stored blood samples, comparing those from individuals with presymptomatic to late-stage Alzheimer’s disease with those from individuals without the disease.

Statistical analyses of the two groups of blood samples showed that in the Alzheimer’s samples, there were 18 proteins with distinctly different concentrations from those in normal individuals.

Previous articleMonogram to Assist Progenics with Advancement of Early-Stage HIV Therapy
Next articlePlethora Could Earn up to $25M in Cash through Financing Deal with Paul Capital Healthcare